Filter results

Clinical Studies

Contact Us for the Latest Status

Closed for Enrollment

  • Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment Rochester, Minn.

    This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.